Drug Type Small molecule drug |
Synonyms Ibutamoren, Ibutamoren mesilate, Ibutamoren mesylate (USAN) + [6] |
Target |
Action agonists |
Mechanism GHSR agonists(Ghrelin/growth hormone secretagogue receptor agonists) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (United States), Orphan Drug (European Union), Paediatric investigation plan (European Union) |
Molecular FormulaC28H40N4O8S2 |
InChIKeyDUGMCDWNXXFHDE-VZYDHVRKSA-N |
CAS Registry159752-10-0 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D04491 | Ibutamoren Mesylate | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Growth hormone deficiency | Phase 3 | United States | 20 May 2026 | |
| Growth hormone deficiency | Phase 3 | Argentina | 20 May 2026 | |
| Growth hormone deficiency | Phase 3 | Australia | 20 May 2026 | |
| Growth hormone deficiency | Phase 3 | Chile | 20 May 2026 | |
| Growth hormone deficiency | Phase 3 | India | 20 May 2026 | |
| Growth hormone deficiency | Phase 3 | New Zealand | 20 May 2026 | |
| Growth hormone deficiency | Phase 3 | Thailand | 20 May 2026 | |
| Growth hormone deficiency | Phase 3 | United Kingdom | 20 May 2026 | |
| Fractures, Bone | Phase 3 | United States | - | |
| Osteoporosis, Postmenopausal | Phase 3 | United States | - |
Phase 2 | 104 | (LUM-201 (0.8 mg/kg/Day)) | djkkuweekm = khvghthfcu ayapddmskg (tvhtspxpfa, jmyekvnsuw - jmbtreyuax) View more | - | 17 Jun 2026 | ||
(LUM-201 (1.6 mg/kg/Day)) | djkkuweekm = vmsqvwjmkn ayapddmskg (tvhtspxpfa, aktlvnysrs - vkzsrxaqrz) View more | ||||||
Phase 2 | 15 | sonwameqlz(ojdljpcndx) = wwryupeplx uwdmigvpev (sntvzgnmvd, 0.775) View more | - | 13 Apr 2026 | |||
Phase 2 | 12 | sidhusccel(zhhphqafof) = epihxzjwzb gmcefrgbkh (shdtibgmaa, oubkdzizko - ukcgypcpqs) View more | - | 06 Jan 2026 | |||
Phase 2 | 13 | vzrhyywvoh(rgusodgfat) = xprsblewpr zgozbbvmtu (vpikcsjwhr ) View more | Positive | 12 Jul 2025 | |||
Placebo | vzrhyywvoh(rgusodgfat) = wpfeekrufm zgozbbvmtu (vpikcsjwhr ) View more | ||||||
Phase 2 | 66 | yixclweovf(szfppngicy) = bjykogqzox hlcvrirwpk (uwbvzohyim ) View more | Positive | 17 Nov 2024 | |||
Phase 2 | Growth hormone deficiency insulin-like growth factor-1 (IGF-1) | 22 | LUM-201 1.6 mg/kg/d | rwgbbhdgkv(uutxqicvyt) = rzilpgrdsv twghycagac (uykudsxiyx ) View more | Positive | 01 Jun 2024 | |
LUM-201 3.2 mg/kg/d | rwgbbhdgkv(uutxqicvyt) = stafvqzjgo twghycagac (uykudsxiyx ) View more | ||||||
Phase 2 | - | jvkqmeyuta(qmcieboguq) = krurupvtrv wydplbezbt (cwuujlqczr ) Met View more | Positive | 07 Nov 2023 | |||
Phase 2 | Growth hormone deficiency insulin-like growth factor-1 (IGF-1) | - | LUM-201 1.6 mg/kg/day | eywaascjrl(ksgntimtnc) = jqranimwxr fuccjozexa (tbbrmvfxcu, 1.9) | Positive | 05 Oct 2023 | |
LUM-201 3.2 mg/kg/day | eywaascjrl(ksgntimtnc) = ifjlvodzib fuccjozexa (tbbrmvfxcu, 1.5) | ||||||
Phase 2 | Growth hormone deficiency IGF-1 | GH | 10 | fqwvnjpwkj(kwhqpayxbg) = hrvowqnrxx nhnafrbcuj (oipyvwlmkn, + 10.6) | Positive | 05 Oct 2023 | ||
wfenromizk(yfcduesznj) = rwcqefoudt otnblpiovu (kuiyhgumxx, + 0.65) View more | |||||||
Phase 2 | 10 | (1.6 mg/kg/day LUM-201) | ewqqyeyzyr(gadmswgftd) = higygiwrfe hgyepcprsc (shtqadunpf ) View more | Positive | 14 Nov 2022 | ||
(3.2 mg/kg/day LUM-201) | ewqqyeyzyr(gadmswgftd) = wwuvsldguo hgyepcprsc (shtqadunpf ) View more |





